Ocriplasmin is a proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula. Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.
- Mechanism
- Curator reviewed
Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).
- Primary indication
- Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.Curator reviewed · 1 structured indication
- Formula / weight
- C1214H1890N338O348S14 · 27250.0 Da
- First approval
- Canada, 2018 · United States, 2012
- Also known as
- Microplasmin · Microplasmin (synthetic human) · Recombinant human microplasmin
Resolves to
What you can answer from here — as of September 13, 2026
Which drugs share a target with Ocriplasmin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account